Actualités Quantum Genomics - ALQGC | Actions Euronext

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in...

Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...

Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...

Quantum Genomics announces the appointment of its new Scientific Advisory Board

PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...

Quantum Genomics Publishes its Results for Fiscal Year 2021 and Provides a Corporate Update

PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...

Quantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€

Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and...

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

Launch of capital increase of approximately €15 million for institutional investors with cancellation of the...

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...

Quantum Genomics Announces Granting of New Patents Protecting QGC606

PARIS, March 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...

Stéphane Cohen Joins Quantum Genomics as Director of Global Operations

PARIS, March 14, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...

Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar

Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as...

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quantum Genomics (ALQGC)

Outils de qualité professionnelle, pour des investisseurs individuels.

ALQGC Actualités

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Publishes its Results for Fiscal Year 2021 and Provides a Corporate Update

Quantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Stéphane Cohen Joins Quantum Genomics as Director of Global Operations

Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quantum Genomics (ALQGC) Actualités

Quantum Genomics (ALQGC)

Outils de qualité professionnelle, pour des investisseurs individuels.

ALQGC Actualités

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Publishes its Results for Fiscal Year 2021 and Provides a Corporate Update

Quantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Stéphane Cohen Joins Quantum Genomics as Director of Global Operations

Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres